GEN-MKT-18-7897-A
Oct 3, 2017 | Blogs, Technology | 0 comments
If you are a scientist working with complex assays, finding a way to significantly improve selectivity of detection could solve some of your biggest analytical headaches. Are we right? If so, then you are in the right place.
If you are confronted with assay selectivity challenges, then explore the SelexION® Differential Mobility Spectrometry (DMS) technology. SelexION technology delivers analyte separation that is orthogonal to mass separation, helping you to achieve a more selective MS assay, without returning to method development and complex sample preparation strategies.
If this is the first time you have read about the SelexION device, we suggest you also read the previous blog in this series where we introduced the ‘Science Behind SelexION DMS Technology’. Before you click on the link, keep reading to find out the top five ways that SelexION addresses your biggest analytical challenges.
Overcome these five common challenges and achieve a new dimension in selectivity by incorporating SelexION DMS separation on your SCIEX Triple Quad™, QTRAP®, or TripleTOF® System.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network